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Objective: To determine the pharmacokinetics and safety of RAD001 (everolimus) in
Japanese patients with advanced solid tumors.
Methods: An open-label, non-randomized, dose-escalation Phase I study of RAD001 admi-
nistered continuously once daily in a 28-day cycle was performed. The study had a ‘3 þ 3’
design, with three patients recruited to each of three successive cohorts treated with RAD001
at 2.5, 5.0 or 10.0 mg/day.
Results: The pharmacokinetics of RAD001 in Japanese patients were similar to those pre-
viously determined in Caucasians. The drug safety proﬁle was consistent with that of a mam-
malian target of rapamycin inhibitor. No dose-limiting toxicities were observed. One patient
with esophageal cancer and one with gastric cancer treated with RAD001 at 10 mg/day
showed marked tumor responses.
Conclusions: Treatment of Japanese cancer patients with RAD001 may be undertaken with
the expectation that previously determined pharmacokinetic and safety proﬁles apply. The
drug may hold promise for treatment of esophageal and gastric cancer.
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INTRODUCTION
Mammalian target of rapamycin (mTOR) is an intracellular
protein kinase that mediates cellular responses to growth
factors, nutrients and changes in energy status and thereby
plays an important role in the regulation of cell growth, cell
division and angiogenesis. It controls ribosome biosynthesis
and the transcription of genes for many proteins that
participate in the cell cycle, metabolism, nutrient transport
or utilization, or the response to hypoxia. Various signaling
defects upstream of mTOR, some of which are relatively
common, have been identiﬁed in cancer cells and result in
loss of cell growth control, unrestrained proliferation, tumor
angiogenesis, and other malignant characteristics. Defects in
mTOR itself have not been identiﬁed in cancer, rendering
this kinase both a well-situated and stable target for thera-
peutic intervention in cancers driven by defects in the
mTOR signaling pathway (1–3).
RAD001 (everolimus) blocks the mTOR pathway by
forming a complex with the immunophilin FK506-binding
protein-12, which also binds mTOR with high afﬁnity. This
drug has exhibited antitumor activity with a variety of
cancer cells both in vitro (4–9) and in vivo (10–12). In
addition, the anticancer effects of RAD001 complement
those of chemotherapy, radiation, hormonal agents and tar-
geted therapeutics (13–15). RAD001 inhibits tumor growth
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angiogenic growth factors and thereby reducing the prolifer-
ation of neovascular endothelial cells (3). Phase I studies of
RAD001 have shown sustained inhibition of mTOR activity
in tumor tissue at oral doses of  20 mg weekly or 5–10 mg
daily (16). Continuous daily dosing with RAD001 has been
found to result in a more profound and sustained inhibition
of mTOR than that achieved with an intermittent weekly
schedule (17,18).
We have now performed a Phase I trial of RAD001 admi-
nistered daily to Japanese patients with advanced solid
tumors. The purpose of our study was to assess the pharma-
cokinetics, safety and tolerability of escalating oral doses of
RAD001 in this patient population. An additional objective
included evaluation of antitumor activity.
We herein report that RAD001 can be safely administered
at daily doses up to 10 mg to Japanese patients with
advanced solid malignancies. A dosage of 10 mg/day is rec-
ommended for further development.
PATIENTS AND METHODS
PATIENT POPULATION
Japanese individuals  20 years of age with a histologically
conﬁrmed diagnosis of an advanced tumor refractory to or
unsuitable for existing standard therapy were included in the
study if they had .1 measurable lesion, a life expectancy of
 3 months, and adequate or acceptable renal [serum creati-
nine concentration of  1.5  the upper limit of normal
(ULN)], liver (serum bilirubin concentration of  1.25 
ULN, serum transaminase activity of  3  ULN and serum
albumin concentration of  3.5 g/dl) and bone marrow
(absolute neutrophil count of  1500/mm
3, platelet count of
 1   10
5/mm
3 and hemoglobin concentration of  9g / d l )
function. Patients with tumors or metastases in the central
nervous system, uncontrolled infection, gastrointestinal
impairment disease, active bleeding diathesis, other concur-
rent or uncontrolled medical disease, or a history of coagu-
lation disorders as well as those under treatment with strong
inhibitors or inducers of isoenzyme CYP3A4 were excluded
from the study. All subjects provided written informed
consent to participation in the study, which was approved by
the Institutional Review Board of each participating center
and was performed in accordance with the Declaration of
Helsinki and Good Clinical Practice guidelines.
STUDY DESIGN
The study was an open-label, non-randomized, dose-
escalation Phase I trial of RAD001 administered on a con-
tinuous once-daily schedule in a 28-day cycle to adult
Japanese patients, with continuation of therapy after 28 days
in the absence of progressive disease. The primary objective
was to evaluate the tolerability/safety and dose-limiting tox-
icity (DLT) of RAD001, up to the dose level of 10 mg/day
which is being used in the global study. The study had a
‘3 þ 3’ design, with three patients recruited to each of three
successive cohorts treated with RAD001 at 2.5, 5.0 or
10.0 mg/day. Patients were allowed to receive a higher
RAD001 dose, at the investigator’s discretion, if the higher
dose had been conﬁrmed as tolerable. Treatment was discon-
tinued in the event of progressive disease, DLT, a dose delay
of .14 days (or .42 days for hematologic DLTs), or with-
drawal of consent. A DLT was deﬁned as a hematologic
(anemia, leukopenia, thrombocytopenia or neutropenia) or
non-hematologic adverse event with a grade of  3o ral a b -
oratory abnormality with a grade of  3 that occurred within
the ﬁrst 4 weeks of treatment and was suspected to be
related to RAD001. Standard antiemetic prophylaxis and
anti-hyperlipidemia therapy were allowed. Recruitment was
permitted for Cohort 2 if DLTs were observed in 0/3 or  1/
6 patients in Cohort 1, and for Cohort 3 if DLTs were
observed in 0/3 or  1/6 patients in Cohort 2. DLTs in  2/6
patients in Cohort 1 would result in study discontinuation;
DLTs in  2/6 patients in Cohort 2 or 3 would result in
additional patient enrollment in Cohorts 1 and 2, respect-
ively. The maximum-tolerated dose was deﬁned as the dose
at which two or more patients experienced a DLT in the ﬁrst
cycle.
ASSESSMENTS
Blood samples for pharmacokinetic analysis were collected
on days 1 and 15 of cycle 1 at 0, 1, 2, 4, 6, 8 and 24 h
after RAD001 administration. Blood samples for assessment
of the trough concentration (Cmin)o fR A D 0 0 1w e r e
obtained immediately before administration of the next dose
on days 2, 8, 11, 15 and 16 of cycle 1 and on day 1 of
cycle 2 as well as at the end of the study. Pharmacokinetic
parameters of RAD001 determined for each cohort included
the maximum blood concentration (Cmax), time of
maximum concentration (tmax), area under the concen-
tration-versus-time curve from time 0 to 24 h after drug
administration (AUCt, dosing interval) and apparent sys-
temic clearance (CL/F). Drug safety and tolerability were
assessed according to the NCI Common Terminology
Criteria for Adverse Events (CTCAE) scale, version 3.0.
Patients were monitored for adverse events throughout the
study. Tumor volume was evaluated every 2 months and at
the end of the study according to RECIST. Data were
r e c o r d e df o ru pt o2 8d a y sa f t e rd i s c o n t i n u a t i o no f
treatment.
STATISTICS
The number of patients in each proposed cohort was based
on the standard ‘3 þ 3’ design for dose-escalation studies.
A total of 9–18 patients were planned to assess the safety
and tolerability of RAD001, depending on observed toxici-
ties. Descriptive statistics were used for evaluation of safety,
efﬁcacy and pharmacokinetic outcomes.
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PATIENT CHARACTERISTICS
Between November 2005 and December 2006, nine patients
with advanced, refractory solid tumors were enrolled in the
study at the two participating centers (Kinki University
School of Medicine and National Cancer Center Hospital
East) (Table 1). The median age was 64 years (range, 49–74).
All patients had received prior chemotherapy for their
disease, and most of them had previously undergone cancer-
related surgery. The median durations of RAD001 therapy
were 57 days in the 2.5 mg/day cohort, 42 days in the 5 mg/
day cohort and 98 days in the 10 mg/day cohort. Treatment
was discontinued in all nine patients as a result of either pro-
gressive disease (n ¼ 4), toxicities (n ¼ 2), consent withdra-
wal (n ¼ 2) or death (n ¼ 1, hemorrhage). All patients were
evaluable for drug safety and pharmacokinetics.
SAFETY
DLTs were not observed for any patient in the ﬁrst cycle of
treatment (28 days). Overall, the most common adverse
events of all grades were thrombocytopenia (56% of
patients), leukopenia (33%), anorexia (44%) and rash (44%)
(Table 2). One patient with colon cancer and both lung and
liver metastases was treated at the RAD001 dose of 5 mg/
day experienced grade 2 pneumonitis after 142 days of
therapy. The patient developed cough, and computed tomo-
graphic scan of the chest revealed new ground-glass opaci-
ties. The patient was hospitalized with PaO2 of 72.7 mmHg.
Steroid treatment and discontinuation of RAD001 resulted in
marked improvement of the patient within days. All toxici-
ties of Grade 3 or 4 occurred at the dose of 10 mg/day, but
none occurred in the ﬁrst cycle and therefore did not qualify
as DLTs. One patient with advanced esophageal carcinoma
at a dose of 10 mg/day developed Grade 3 fatigue and sto-
matitis on day 58 and RAD001 was interrupted. The study
drug was restarted on day 66 at a reduced dose of 5 mg/day.
On day 71, the patient visited the hospital because of hemor-
rhage from the right supraclavicular tumor which was a
metastatic focus. Although the patient was treated as an inpa-
tient, the Grade 4 hemorrhage could not be controlled and
the patient died on day 78. Since RAD001 markedly dimin-
ished the size of the patient’s metastatic focus, the cause of
death was hemorrhage from either the right supraclavicular
metastatic focus or the enriched vessels. The study drug did
not seem to be the direct cause of hemorrhage. The other
two patients in the 10 mg/day cohort took RAD001 for .3
months. One patient with colorectal cancer was treated with
10 mg/day and experienced Grade 3 hyperglycemia on day
98. The patient was determined to have progressive disease
on the same day. Another patient in the 10 mg/day cohort
Table 1. Patient characteristics
Characteristic No. of patients
Sex
Male 4
Female 5
Performance status (ECOG)
05
14
Previous therapy
Surgery 8
Chemotherapy 9
Radiotherapy 3
Tumor type
Colorectal cancer 3
Lung cancer 3
Esophageal cancer 1
Gastric cancer 1
Thyroid cancer 1
The median (range) age was 64 (49–74) years. ECOG, Eastern Cooperative
Oncology Group.
Table 2. Number of patients with adverse events in all courses thought to
be attributable to RAD001
Adverse event RAD001 dose (mg/day) Total
2.5 (n ¼ 3) 5 (n ¼ 3) 10 (n ¼ 3)
G1/2 G3/4 G1/2 G3/4 G1/2 G3/4
Thrombocytopenia 0 0 2 0 3 0 5
Leukopenia 1 0 2 0 0 0 3
Neutropenia 1 0 0 0 0 0 1
Anemia 0 0 0 0 1 0 1
Anorexia 1 0 2 0 1 0 4
Rash 0 0 1 0 3 0 4
Stomatitis 1 0 0 0 0 1 2
Nausea 1 0 0 0 1 0 2
Mucosal inﬂammation 0 0 0 0 2 0 2
Diarrhea 0 0 2 0 0 0 2
Fatigue 0 0 1 0 0 1 2
Weight decreased 1 0 0 0 1 0 2
Elevated ALT or AST 2 0 0 0 0 0 2
Hyperglycemia 0 0 0 0 0 1 1
Hemorrhage 0 0 0 0 0 1 1
Pneumonitis 0 0 1 0 0 0 1
Hypertension 1 0 0 0 0 0 1
Glucose tolerance impaired 0 0 1 0 0 0 1
Includes all adverse events occurring in two or more patients or were
 Grade 2. G, grade; ALT, alanine aminotransferase; AST, aspartate
aminotransferase.
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RAD001 due to disease progression on day 154.
PHARMACOKINETICS
Pharmacokinetic parameters of RAD001 are summarized in
Table 3. The Cmax of RAD001 was apparent 2 h after admin-
istration of a single dose of the oral drug (Table 3 and
Fig. 1A). The Cmin of RAD001 indicated that a steady state
was attained after  8 days of repeated once-daily oral
dosing (Fig. 1B). Determination of the AUCt on days 1 and
15 revealed that the exposure to RAD001 achieved after
multiple dosing was about twice that achieved after a single
dose (Table 3). On day 1, Cmax and AUCt increased almost
dose-proportionally. At steady state (day 15), Cmax and
AUCt increased with increment of dose but dose-
proportionality was not clear due to large inter-individual
variability in the 5 mg/day cohort.
TUMOR RESPONSE
Among seven patients evaluable for tumor response, obvious
tumor shrinkage was observed in two patients treated at the
dose level of 10 mg/day. A 60-year-old male with advanced
esophageal carcinoma who had been treated with seven prior
chemotherapy regimens started treatment with RAD001 at
Table 3. Pharmacokinetic parameters of RAD001
RAD001 dose (mg/day)
2.5 (n ¼ 3) 5 (n ¼ 3) 10 (n ¼ 3)
Day 1
tmax (h)
Median 1.98 1.00 2.00
Range 0.98–2.00 1.00–1.95 1.92–2.00
Cmax (ng/ml) 15.1+2.48 31.5+3.40 49.4+14.8
AUCt (ng h/ml) 85.2+18.7 211+50.0 401+51.6
Day 15
tmax (h)
Median 1.92 1.98 2.02
Range 1.00–1.98 1.93–1.98 2.00–2.20
Cmax (ng/ml) 16.8+1.33 57.6+17.6 65.9+1.40
AUCt (ng h/ml) 134+24.1 543+189 711+113
CL/F (l/h) 19.1+3.26 9.94+3.21 14.3+2.23
Data are means+SD unless indicated otherwise. tmax, time of maximum concentration; Cmax, maximum blood concentration; AUCt, area under the
concentration-versus-time curve from time 0 to 24 h after drug administration; CL/F, apparent systemic clearance.
Figure 1. Pharmacokinetics of RAD001. (A) Blood concentration of RAD001 after administration of a single oral dose (2.5, 5 or 10 mg) on day 1 of cycle 1.
Data are means+SD. (B) Blood trough concentration (Cmin) of RAD001 during continuous oral dosing for 29 days (cycle 1). Data are means+SD.
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tomography revealed that lymph nodes with metastases in
the right supraclavicular region had shrunk markedly
(Fig. 2A). A 64-year-old male with gastric adenocarcinoma
and liver metastases who had undergone four prior che-
motherapy regimens showed a partial response to RAD001
that persisted for .4 months at the dose of 10 mg/day
(Fig. 2B).
DISCUSSION
Evidence implicating the phosphatidylinositol 3-kinase–
Akt–mTOR signaling pathway in the pathogenesis of a
variety of malignancies has prompted the development of
therapeutic strategies to modulate this pathway. RAD001 is
an oral inhibitor of the mTOR pathway, and we have now
performed a dose-escalation Phase I study of this drug in
Japanese patients with advanced solid tumors in order to
evaluate its safety and pharmacokinetics. Therapy with
RAD001 at oral doses of up to 10 mg once daily was rela-
tively well tolerated in the study subjects. Indeed, the safety
and tolerability of RAD001 in the Japanese patients were
similar to those observed in previous studies with larger
populations of Caucasian patients, for whom the most
common drug-related toxicities included rash, stomatitis and
fatigue. Previous studies have reported that patients receiving
RAD001 manifested hyperglycemia and hyperlipidemia,
probably as a result of inhibition of mTOR-regulated glucose
and lipid metabolism (16,18,19). Grade 3 hyperglycemia
was observed in one patient treated with 10 mg/day, whereas
hyperlipidemia was not observed in our study. One patient in
our study developed pneumonitis of Grade 2, with this
condition having previously been identiﬁed as a potential
class-related toxicity for mTOR inhibitors that should be
monitored in clinical trials with these agents (16–20).
However, the condition of pneumonitis in our study was
reversible after discontinuation of RAD001 treatment. The
pharmacokinetic proﬁle of RAD001 in Japanese patients was
also similar to that in Caucasian patients. RAD001 was
absorbed rapidly, with the Cmax being achieved as early as
1–2 h after oral administration. A recent Phase I study of
RAD001 performed in Europe and the USA showed that the
mean (+SD) Cmax in patients with advanced cancer was
32+9a n d6 1+17 ng/ml at daily doses of 5 and 10 mg,
respectively, with a mean AUCt of 238+77 and 514+
231 ng h/ml, respectively (16). These results for Caucasian
patients are similar to those obtained here with Japanese
patients, especially for the dose level of 10 mg/day (Cmax of
65.9+1.40 ng/ml and AUCt of 711+113 ng h/ml. Given
the limited number of patients in both studies, these results
suggest that there are no substantial differences in the phar-
macokinetics of RAD001 between the two populations.
RAD001 has already undergone extensive clinical testing in
the setting of renal and cardiac transplantation (21,22). Our
present data are also supported by observations with
673 renal transplant patients who received RAD001 (23).
This large cohort included 80% Caucasian patients and 2.5%
patients of Asian origin with no signiﬁcant differences in
clearance of RAD001 being apparent between the Asian and
Caucasian patients. The data from this study, combined with
those from previous studies, suggest that the pharmacoki-
netic and safety data for RAD001 obtained in larger clinical
trials with Caucasian patients are likely applicable to the
Japanese population.
Figure 2. Computed tomography images of tumor response to RAD001 treatment. (A) Shrinkage of metastases in supraclavicular lymph nodes in a patient
with esophageal cancer. (B) Shrinkage of liver metastases in a patient with gastric cancer.
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study, two of three patients treated with RAD001 at a daily
dose of 10 mg manifested marked tumor shrinkage. This anti-
tumor activity occurred in patients with esophageal and
gastric cancer. One esophagogastric cancer patient also exhib-
ited a partial response to RAD001 treatment at a daily dose
of 5 mg in a previous Phase I study (16). The likelihood that
these ﬁndings will extend to other patients is supported by
recent studies suggesting that defects in the mTOR signaling
pathway are important in the pathogenesis of these cancers.
mTOR is an upstream regulator of hypoxia-inducible
factor-1a, which is a key mediator of gastric cancer growth
(24). Pre-clinical studies have shown that the mTOR inhibitor
rapamycin inhibits the growth of human gastric adenocarci-
noma cell lines, gastric cancer, gastrointestinal tumors, and
the development of peritoneal carcinomatosis from gastric
cancer in vitro or in vivo (24–27).
In conclusion, the results of our Phase I study suggest that
RAD001 can be safely administered at a daily dose of 10 mg
to Japanese patients with advanced solid malignancies. The
pharmacokinetic characteristics of RAD001 in Japanese
patients did not appear to differ from those previously
observed in Caucasian patients. The safety proﬁle and poten-
tial broad-spectrum efﬁcacy of RAD001 thus warrant
additional clinical evaluation of this new agent.
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